Anaplastic Astrocytoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anaplastic Astrocytoma – Drugs In Development, 2024 report and make more profitable business decisions.
Anaplastic astrocytoma is a grade III tumor that accounts for 2% of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking, and seizures. Anaplastic astrocytoma is most common in men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed, and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.
The Anaplastic Astrocytoma drugs in development market research report provide comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anaplastic Astrocytoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 46 molecules, with 39 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anaplastic Astrocytoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anaplastic Astrocytoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anaplastic Astrocytoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAminex Therapeutics Inc
AngioChem Inc
Aveta Biomics Inc
Bayer AG
Beijing zhikangbo Medical Oncology Research Co Ltd
Boehringer Ingelheim International GmbH
BPGbio Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Capital Medical University
Chimerix Inc
Everfront Biotech Inc
Fore Biotherapeutics Inc
Geneos Therapeutics Inc
Henry Ford Health System
Ipsen SA
Istari Oncology Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Lee's Pharmaceutical Holdings Ltd
Merck KGaA
MimiVax LLC
Mustang Bio Inc
Nascent Biotech Inc
Nationwide Children's Hospital
Novartis AG
Orbus Therapeutics Inc
Orphelia Pharma SAS
Pfizer Inc
PTC Therapeutics Inc
Pyxis Oncology Inc
Stemline Therapeutics Inc
TheraBiologics Inc
Treovir LLC
UAB Minority Health and Health Equity Research Center
UCLAs Jonsson Comprehensive Cancer Center
University of Miami
Wayshine Biopharma Inc
Wuhan Binhui Biopharmaceutical Co Ltd
Wurzburg University Hospital
Xynomic Pharmaceuticals Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anaplastic Astrocytoma reports